AR035590A1 - DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS - Google Patents

DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS

Info

Publication number
AR035590A1
AR035590A1 ARP010104788A AR035590A1 AR 035590 A1 AR035590 A1 AR 035590A1 AR P010104788 A ARP010104788 A AR P010104788A AR 035590 A1 AR035590 A1 AR 035590A1
Authority
AR
Argentina
Prior art keywords
radical
group
hydrogen
11beta
atom
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Priority to ARP010104788 priority Critical patent/AR035590A1/en
Publication of AR035590A1 publication Critical patent/AR035590A1/en

Links

Landscapes

  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados 8beta-sustituidos de 11beta-pentil- y 11beta-hexil-estra-1,3,5(10)-trieno de fórmula general (1), en la cual: R2 significa hidrógeno, halógeno (F, Cl, Br, I); un radical R18 o R18O, donde R18 significa hidrógeno, un radical alquilo o acilo (ambos de cadena lineal o ramificada, saturados o insaturados con hasta 6 átomos de carbono), un grupo trifluorometilo, un radical R19SO2O, donde R19 significa un grupo R20R21N, donde R20 y R21 son, independientemente entre sí, un hidrógeno, un radical alquilo C1-5, un grupo C(O)R22, donde R22 significa un radical hidrocarburo (opcionalmente sustituido, de cadena lineal o ramificada, saturado o hasta triinsaturado, parcial o totalmente halogenado) con hasta 10 átomos de carbono, un radical cicloalquilo C3-7 opcionalmente sustituido, un radical cicloalquilo C4-15 opcionalmente sustituido o un radical arilo, heteroarilo o aralquilo opcionalmente sustituido, o, junto con el átomo de N, un radical polimetilenimino C4-6 o un radical morfolino); R3 significa R18O, R19SO2O, OC(O)R22, con R18, R19, R22 con el significado indicado en R2, así como R18 adicionalmente un radical arilo, hetarilo o aralquilo; R6, R6' significa un hidrógeno cada uno o R6 significa un enlace adicional con R7; R7, R7' significa un hidrógeno cada uno o R7 significa un enlace adicional con R6; R8 significa un radical alquilo, alquenilo (de cadena lineal o ramificada, parcial o totalmente halogenado), con hasta 5 átomos de carbono cada uno, un radical etinilo o prop-1-inilo; R11 significa un radical n-pentilo o n-hexilo; R14 significa hidrógeno o un enlace adicional con R15; R15 significa hidrógeno o un enlace adicional con R14 o R16; R16 significa hidrógeno o un enlace adicional con R15; R15', R16' significan, independientemente entre sí, hidrógeno, halógeno, un grupo R18O, R19SO2O u OC(O)R22 con R18, R19, R22 con el significado indicado en R2; R17, R17' significan un átomo de hidrógeno cada uno, un átomo de hidrógeno y un átomo de halógeno; un átomo de hidrógeno y un grupo benciloxi; un átomo de hidrógeno y un grupo R19SO2-O-; un grupo R18 y un grupo -C(O)R22 u -O-C(O)R22; un grupo R18-O- y un grupo R18-; un grupo R18-O- y un grupo -O-C(O)R22, con R18, R19 y R22 con el significado indicado en R2 o R17, R17' significan juntos un grupo =CR23R24, donde R23 y R24 significan, independientemente entre sí, un átomo de hidrógeno y un átomo de halógeno, o representan juntos un átomo de oxígeno; como principios activos farmacéuticos que presentan in vitro una mayor afinidad con las preparaciones de receptores de estrógeno de próstata de rata que con las preparaciones de receptores de estrógeno de útero de rata y que in vivo desarrollan preferentemente un efecto anticonceptivo preferencial en el ovario sin estimular el útero. También se describen las composiciones farmacéuticas que contienen estos compuestos y el uso de los mismos para preparar medicamentos destinados a la contracepción masculina, así como al tratamiento de enfermedades ováricas proliferativas benignas o malignas como por ejemplo, carcinomas ováricos y tumores celulares de la granulosa.8beta-substituted derivatives of 11beta-pentyl- and 11beta-hexyl-estra-1,3,5 (10) -triene of general formula (1), in which: R2 means hydrogen, halogen (F, Cl, Br, I ); an R18 or R18O radical, where R18 means hydrogen, an alkyl or acyl radical (both straight or branched chain, saturated or unsaturated with up to 6 carbon atoms), a trifluoromethyl group, a R19SO2O radical, where R19 means an R20R21N group, where R20 and R21 are, independently of each other, a hydrogen, a C1-5 alkyl radical, a C (O) R22 group, where R22 means a hydrocarbon radical (optionally substituted, straight or branched chain, saturated or even tri-unsaturated, partial or fully halogenated) with up to 10 carbon atoms, an optionally substituted C3-7 cycloalkyl radical, an optionally substituted C4-15 cycloalkyl radical or an optionally substituted aryl, heteroaryl or aralkyl radical, or, together with the N atom, a radical C4-6 polymethyleneimino or a morpholino radical); R3 means R18O, R19SO2O, OC (O) R22, with R18, R19, R22 with the meaning indicated in R2, as well as R18 additionally an aryl, heteroaryl or aralkyl radical; R6, R6 'means one hydrogen each or R6 means an additional bond with R7; R7, R7 'means one hydrogen each or R7 means an additional bond with R6; R8 means an alkyl, alkenyl radical (straight or branched chain, partially or totally halogenated), with up to 5 carbon atoms each, an ethynyl or prop-1-inyl radical; R11 means an n-pentyl or n-hexyl radical; R14 means hydrogen or an additional bond with R15; R15 means hydrogen or an additional bond with R14 or R16; R16 means hydrogen or an additional bond with R15; R15 ', R16' means, independently of each other, hydrogen, halogen, a group R18O, R19SO2O or OC (O) R22 with R18, R19, R22 with the meaning indicated in R2; R17, R17 'means a hydrogen atom each, a hydrogen atom and a halogen atom; a hydrogen atom and a benzyloxy group; a hydrogen atom and an R19SO2-O- group; a group R18 and a group -C (O) R22 or -O-C (O) R22; an R18-O- group and an R18- group; a group R18-O- and a group -OC (O) R22, with R18, R19 and R22 with the meaning indicated in R2 or R17, R17 'together means a group = CR23R24, where R23 and R24 mean, independently of each other, a hydrogen atom and a halogen atom, or together represent an oxygen atom; as pharmaceutical active ingredients that have a greater affinity in vitro with rat prostate estrogen receptor preparations than with rat uterine estrogen receptor preparations and that in vivo preferentially develop a preferential contraceptive effect on the ovary without stimulating the uterus. Also described are the pharmaceutical compositions containing these compounds and the use thereof to prepare drugs intended for male contraception, as well as the treatment of benign or malignant proliferative ovarian diseases such as ovarian carcinomas and granulose cell tumors.

ARP010104788 2001-10-12 2001-10-12 DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS AR035590A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP010104788 AR035590A1 (en) 2001-10-12 2001-10-12 DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP010104788 AR035590A1 (en) 2001-10-12 2001-10-12 DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS

Publications (1)

Publication Number Publication Date
AR035590A1 true AR035590A1 (en) 2004-06-16

Family

ID=42632438

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104788 AR035590A1 (en) 2001-10-12 2001-10-12 DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS

Country Status (1)

Country Link
AR (1) AR035590A1 (en)

Similar Documents

Publication Publication Date Title
RU2007101304A (en) PROGESTERON RECEPTOR MODULAR CONTAINING PYRROL-OXINDOL DERIVATIVES AND APPLICATION
AR034091A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A SELECTIVE MODULATOR OF THE STROGEN RECEIVER; METHODS OF TREATMENT AND PREVENTION OF INSULIN RESISTANCE AND A SELECTIVE MODULATOR COMPOUND OF THE STROGEN RECEIVER
MXPA02010066A (en) 8szlig; HYDROCARBYL SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS.
US6407101B1 (en) Cyanopyrroles
PE20030727A1 (en) 17OALKYL-17ß-OXI-STRATRENES, INTERMEDIARY PRODUCTS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RU2007101303A (en) PROGESTERON RECEPTOR MODULATORS CONTAINING PYRROL-OXINDOL DERIVATIVES AND THEIR APPLICATION
TW200731969A (en) Use of progesterone receptor modulators
CR7611A (en) USE OF CILOTIOCARBAMATE DERIVATIVES IN TREATMENT OF CONDITIONS RELATED TO HORMONE
PE20000008A1 (en) PHARMACEUTICAL FORMULATIONS TO DELIVER SUSTAINED DRUGS
RU97104120A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
BRPI0516243B8 (en) use of a sexual steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3b, 17b-diol and 4-androsten-3,17-dione, use of that precursor in association with a 5 selective estrogen receptor modulator for uterine and mammary gland protection against cancer, pharmaceutical composition and kit
CY1105957T1 (en) USE OF ESTROGEN COMPOUNDS IN COMBINATION WITH PROGESTOGEN COMPOUNDS IN HORMONE REPLACEMENT THERAPY
CY1108093T1 (en) MEDICINAL DELIVERY SYSTEM CONSISTING OF tetrahydroxylated estrogen for use in hormonal contraception
ES2152671T3 (en) PROGESTERONE DERIVATIVES REPLACED IN POSITION 21 AS NEW ANTIPROGESTATIONAL AGENTS.
AR011480A1 (en) ACIL-ANILIDS SUBSTITUTED WITH CYCLICAL RADICALS (HETERO), NON-STEROIDAL, WITH GESTÁGENA AND MIXED ANDROGENA ACTIVITY.
PA8583201A1 (en) NEW PIRAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
CY1105953T1 (en) COMPOSITIONS FOR RELEASE OF DRUG COMBINATIONS
PE20080995A1 (en) 18-METHYL-19-NOR-ANDROST-4-EN-17,17-ESPIROETERES (18-METHYL-19-NOR-20-ESPIROX-4-EN-3-ONAS), AS WELL AS PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM
AR018330A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE MACROLIDES AS ACTIVE AGENTS FOR THE THERAPY AND PROPHYLAXIS OF SKIN DISEASES
AR034392A1 (en) COMPOUNDS DERIVED FROM 3, 16-DIHIDROXI-ESTRA-1,3,5 (10) -TRIENO, EMPLOYMENT OF THE SAME AND STRUCTURAL PARTS OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ITMI922331A1 (en) USE OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES, FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL IN THE PREVENTION AND THERAPY OF ABORTION AND PRE-TERM BIRTH AND IN GENERAL FOR THE TREATMENT OF THE MANAGEMENT
CU22412A1 (en) A natural mixture composed of superior primary aliphatic alcohol obtained from bees wax for treating gastric ulcers and duodenals which also present anti-inflammatory activity
AR035590A1 (en) DERIVATIVES 8 BETA-SUBSTITUTES OF 11BETA-PENTIL- AND 11BETA-HEXIL-ESTRA-1,3,5 (10) -TRIENO, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THESE DERIVATIVES TO PREPARE MEDICATIONS
GT199800039A (en) ATROPISOMEROS OF 3-HETEROARIL-4 (3H) -QUINAZOLINONAS.
TR200400241T4 (en) Transdermal administration of lasofoxifene

Legal Events

Date Code Title Description
FB Suspension of granting procedure